Pulmonary Embolectomy:

Similar documents
Case. Case. Management of Pulmonary Embolism in the ICU

RISK STRATIFICATION OF PATIENTS WITH ACUTE SYMPTOMATIC PULMONARY EMBOLISM. David Jiménez, MD, PhD, FCCP Ramón y Cajal Hospital, IRYCIS Madrid, Spain

Acute Pulmonary Embolism and Deep Vein Thrombosis. Barbara LeVarge MD Beth Israel Deaconess Medical Center Pulmonary Hypertension Center COPYRIGHT

Surgical Thrombectomy for PE: Is it Making a Comeback

PE and DVT. Dr Anzo William Adiga WatsApp or Call Medical Officer/RHEMA MEDICAL GROUP

The spectrum of clinical outcome of PE

Innovative Endovascular Approach to Pulmonary Embolism by Ultrasound Enhanced Thrombolysis. Prof. Ralf R.Kolvenbach MD,PhD,FEBVS

Risk factors for DVT. Venous thrombosis & pulmonary embolism. Anticoagulation (cont d) Diagnosis 1/5/2018. Ahmed Mahmoud, MD

Venous thrombosis & pulmonary embolism. Ahmed Mahmoud, MD

Pulmonary Thromboembolism

Single Center 4 year series of 114 consecutive patients treated for massive and submassive PE. Mark Goodwin, MD

Epidemiology. Update on Pulmonary Embolism. Keys to PE Management 5/5/2014. Diagnosis. Risk stratification. Treatment

DVT Pathophysiology and Prophylaxis in Medically Hospitalized Patients. David Liff MD Oklahoma Heart Institute Vascular Center

Thrombolysis in PE. Outline. Disclosure. Overview on Pulmonary Embolism. Hot Topics in Emergency Medicine 2012 Midyear Clinical Meeting

Severe pulmonary embolism: surgical aspects. Oliver Reuthebuch Clinic for Cardiac Surgery University Hospital Basel Switzerland

Venous Thrombosis. Magnitude of the Problem. DVT 2 Million PE 600,000. Death 60,000. Estimated Cost of VTE Care $1.5 Billion/year.

Pulmonary embolism. Paweł Balsam

CHAPTER 2 VENOUS THROMBOEMBOLISM

Slide 1. Slide 2. Slide 3. Outline of This Presentation

Innovative Endovascular Approach to Pulmonary Embolism by Ultrasound Enhanced Thrombolysis. Prof. Ralf R.Kolvenbach MD,PhD,FEBVS

Dr. Riaz JanMohamed Consultant Haematologist The Hillingdon Hospital Foundation Trust

Management of Pulmonary Embolism. Michael Hooper, M.D., MSc Associate Professor, Pulmonary and Critical Care Medicine Eastern Virginia Medical School

Ultrasound-enhanced, catheter-directed thrombolysis for pulmonary embolism

October 2017 Pulmonary Embolism

Management of Massive and Sub-Massive Pulmonary Embolism

Pulmonary Embolism. Pulmonary Embolism. Pulmonary Embolism. PE - Clinical

Disclosures. Objectives

Mark H. Meissner, MD Peter Gloviczki Professor of Venous & Lymphatic Disorders University of Washington School of Medicine

PULMONARY EMBOLISM (PE): DIAGNOSIS AND TREATMENT

Massive and Submassive Pulmonary Embolism: 2017 Update and Future Directions

Disclosures. DVT: Diagnosis and Treatment. Questions To Ask. Dr. Susanna Shin - DVT: Diagnosis and Treatment. Acute Venous Thromboembolism (VTE) None

Jessica Bryan, Natalia Evans, Karlyn Henderson, & Whitney Parks

Epidemiology: Incidence VTE: Mortality Morbidity Risk Factors: Acute Chronic : Genetic

Misunderstandings of Venous thromboembolism prophylaxis

PULMONARY EMBOLISM -CASE REPORT-

PREVENTION AND TREATMENT OF VENOUS THROMBOEMBOLISM

Is Thrombolysis Only for a Crisis?

DVT PROPHYLAXIS IN HOSPITALIZED MEDICAL PATIENTS SAURABH MAJI SR (PULMONARY,MEDICINE)

Venous Thromboembolism. Prevention

HEMODYNAMIC DISORDERS

Pulmonary embolism. Paweł Balsam MD, PhD

Pulmonary embolism: Acute management. Cecilia Becattini University of Perugia, Italy

VTE Management in Surgical Patients: Optimizing Prophylaxis Strategies

Intraoperative Pulmonary Embolus

Veno-Venous ECMO Support. Chris Cropsey, MD Sept. 21, 2015

Dave Duddleston, MD VP and Medical Director Southern Farm Bureau Life

Echocardiography as a diagnostic and management tool in medical emergencies

RECOMMENDATIONS FOR THE MANAGEMENT OF MASSIVE AND SUBMASSIVE PULMONARY EMBOLISM IN ADULT PATIENTS.

Acute Coronary Syndrome. Sonny Achtchi, DO

Pathophysiology. Tutorial 3 Hemodynamic Disorders

A Diagnostic Dilemma saved by sound

REVIEW ON PULMONARY EMBOLISM

Venous thrombosis is common and often occurs spontaneously, but it also frequently accompanies medical and surgical conditions, both in the community

Management of Intermediate-Risk Pulmonary Embolism

Management of Acute Pulmonary Embolism. Judith Hurdman Consultant Respiratory Physician

Mabel Labrada, MD Miami VA Medical Center

Acute and long-term treatment of VTE. Cecilia Becattini University of Perugia

Policy Specific Section: May 16, 1984 April 9, 2014

Cover Page. The handle holds various files of this Leiden University dissertation

Real life management of CTEPH: patient case

Epidemiology of Pulmonary Embolism (PE)

CURRENT & FUTURE THERAPEUTIC MANAGEMENT OF VENOUS THROMBOEMBOLISM. Gordon Lowe Professor of Vascular Medicine University of Glasgow

Pathology of pulmonary vascular disease. Dr.Ashraf Abdelfatah Deyab. Assistant Professor of Pathology Faculty of Medicine Almajma ah University

Single-Center, Retrospective, Observational Analysis of Patients with Submassive Pulmonary Embolism (PE) Receiving Catheter- Directed Thrombolysis

THROMBOSIS RISK FACTOR ASSESSMENT

Management of Acute Pulmonary Embolism: Anticipating and Responding to Complexity Ahmed Zaky, M.D., M.P.H. University of Alabama, Birmingham, AL

Chapter 1. Introduction

Dr. Rami M. Adil Al-Hayali Assistant Professor in Medicine

Objectives. Venous Thromboembolism (VTE) Prophylaxis. Case VTE WHY DO IT? Question: Who Is At Risk?

Intraoperative application of Cytosorb in cardiac surgery

Extra Corporeal Life Support for Acute Heart failure

Cardiovascular Images

DECLARATION OF CONFLICT OF INTEREST

How long to continue anticoagulation after DVT?

Disclosures. What is a Specialty Vein Clinic? Prevalence of Venous Disease. Management of Venous Disease: an evidence based approach.

Updates in venous thromboembolism. Cecilia Becattini University of Perugia

Understanding Best Practices in Anticoagulation Therapy in Patients with Venous Thromboembolism. Rajat Deo, MD, MTR

DVT - initial management NSCCG

UPMC Critical Care

incidence of cancer-associated thrombosis (CAT) is further increased by additional risk factors such as chemotherapeutic 2

Med Sci Monit, 2016; 22: Grade D. Quality Outstanding

Despite advances in diagnosis and therapy, acute pulmonary embolism (PE)

Pulmonary Hypertension Surgical Options. Primary pulmonary hypertension. Transplantation. Thromboembolic disease Endarterectomy

Extracorporeal Life Support Organization (ELSO) Guidelines for Pediatric Respiratory Failure

DEEP VEIN THROMBOSIS (DVT): TREATMENT

Cover Page. The handle holds various files of this Leiden University dissertation.

Supplemental Appendix. 1. Protocol Definition of Sustained Virologic Response. A patient has a sustained virologic response if:

Safety of Single- Versus Multi-vessel Angioplasty for Patients with AMI and Multi-vessel CAD

COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP)

A 50-year-old woman with syncope

VTE & Medical Patients: Case Scenario

Prevention and management of deep venous thrombosis (DVT) John Fletcher Wound Care Association of New South Wales

Top 5 (or so) Hematology Consults. Tom DeLoughery, MD FACP FAWM. Oregon Health and Sciences University DISCLOSURE

Indications of Coronary Angiography Dr. Shaheer K. George, M.D Faculty of Medicine, Mansoura University 2014

Inferior Venacaval Filters Valuable vs. Dangerous Valuable Annie Kulungowski. Department of Surgery Grand Rounds March 24, 2008

Predicting Venous Thromboembolic Complications following Neurosurgical Procedures

4. Which survey program does your facility use to get your program designated by the state?

Online Supplementary Data. Country Number of centers Number of patients randomized

Cardiovascular Nursing Practice: A Comprehensive Resource Manual and Study Guide for Clinical Nurses 2 nd Edition

Ryan Walsh, MD Department of Emergency Medicine Madigan Army Medical Center

Transcription:

Pulmonary Embolectomy: Recommendation for early surgical intervention Tomas A. Salerno, M.D. Professor of Surgery, University of Miami Miller School of Medicine and Jackson Memorial Hospital

Epidemiology >600,000 patients/year in the US 50,000-200,000 deaths/year in the US 3-month mortality 15-20% 10% of symptomatic PE are fatal at 1 hour

Epidemiology 70% of symptomatic PE have a DVT 50% of patients with a symptomatic DVT have a PE

Age Distribution Goldbaher et al. Lancet (1999)

Virchow s Triad Venous Stasis Hypercoagulability Endothelial Injury

Risk Factors for DVT/PE VENOUS STASIS. immobility (bed rest, travel). paralysis (CVA, SCI). Obesity. heart/respiratory failure. Casting ENDOTHELIAL INJURY. trauma (orthopedic). major surgery (orthopedic). central venous catheters HYPERCOAGULABILITY. previous DVT/PE. malignancy. inflammatory conditions (SLE). sepsis. increased estrogen. acquired/inherited disorders. protein S or C deficiency. ATIII deficiency. factor V Leiden mutation

Clinical Scenario PA obstruction pulmonary vascular resistance (PVR). redistribution of blood flow impairs gas exchange. hyperventilation and bronchoconstriction augments airway resistance. pulmonary edema pulmonary compliance. As RV afterload, RV dilatation/dysfunction and ischemia and subsequent hemodynamic (HD) compromise. cardiac arrest and sudden cardiac death

Clinical Presentation Goldbaher et al. Lancet (1999)

Clinical Scenario

RVD and Mortality Goldbaher et al. Lancet (1999)

In-Hospital Mortality Dalen et al. Arch Irtern Med 2002

Predictor of Mortality RV dilation Normal RV

PA Embolism

PA Embolism

Right Ventricular Distension

Right Ventricular Distension

Specimen

Predictors of mortality

Outcomes Wood et al. Circulation 2002

Traditional PE management

Thrombolytics in Pulmonary Embolism Compared to UFH thrombolytics demonstrate: more rapid improvements in pulmonary vascular resistance improved RV function significantly more bleeding complications Trials all have limitations which include: small sample sizes (8-160 pts) underpowered to evaluate clinical endpoints heterogeneous patient populations

Thrombolytics vs. Surgery Mortality Thrombolytics 33% hemodynamically stable patients with RV dysfunction vs. Pulmonary Embolectomy 11% hemodynamic unstable patients Sukhija et al. Am J Cardiol 2005 33% 23% patients with shock and massive pulmonary Gulba et al. Lancet 1994 Both studies concluded that, medically treated patients, have higher death rate, increased risk of major hemorrhage, and increased recurrence rate of PE.

Pulmonary Embolectomy Past Present and Future Mortality Rates in Earlier Studies of Open Pulmonary Embolectomy Mortality = 8% Mortality = 6%

Surgical Technique: Aorta and Double stage venous cannulation Normothermic CPB with Lung ventilation Main PA opened Oval forcepts removal of clots until clear return Confirmation with TEE of main PA clots removal

Table 1 Patient Characteristics Variables n % Age at surgery 45.31 ± 17.65 (14-76) Gender Male 9 56.2% Female 7 43.7% Procedure Emergent/urgent Salvage Table 1 Patient Characteristics Variables n 9 7% 56.2% 43.7% Age at surgery 45.31 ± 17.65 (14-76) Gender Male 9 56.2% Female 7 43.7% Procedure Emergent/urgent 9 56.2% Salvage 7 43.7% Hospital Stay, days (range) 16.62 ± 16.73 (1-66) Deep Vein Thrombosis 7 43.7% Respiratory Failure 4 25% Hypertension Hospital Stay, days (range) 16.62 ± 16.73 (1-66) 4 25% Renal Failure Deep Vein Thrombosis 7 443.7% 25% Diabetes Respiratory Failure 4 425% 25% Hypertension 4 25% Prior organ transplantation Renal Failure 4 325% 18.7% Congestive Heart Failure Diabetes 4 325% 18.7% Prior organ transplantation 3 18.7% Neoplasia Congestive Heart Failure 3 318.7% 18.7% Prior PE Neoplasia 3 218.7% 12.5% Prior PE 2 12.5% Bacterial endocarditis 1 6.2% Bacterial endocarditis 1 6.2% Hypercoagulable state Hypercoagulable state 1 16.2% 6.2% LVEF 53.43 ± 7.68% ( 40-70 ) EF> 50% 6 37.5% LVEF EF = 31-50% 53.43 10 ± 7.68% 62.5% ( 40-70 ) EF> 50% 6 37.5% EF = 31-50% LVEF (Left Ventricular Ejection Fraction) 10 62.5% LVEF (Left Ventricular Ejection Fraction)

Table 2 Operative Data Variables n % CPB time (min) 43.12 ± 41.65 (9-161) Table 1 Patient Characteristics ICU stay (day) 6.19 ± 5.44 (0-17) Variables n % Age at surgery 45.31 ± 17.65 (14-76) Gender Male 9 56.2% Female 7 43.7% Procedure Emergent/urgent 9 56.2% RV dysfunction Salvage 7 43.7% 7 77.7% Preoperative echo findings (non-salvage patients) Hospital Stay, days (range) 16.62 ± 16.73 (1-66) RV normal 2 22.3% Complications Deep Vein Thrombosis 7 43.7% Respiratory Failure 4 25% Hypertension 4 25% Renal Failure 4 25% Diabetes 4 25% Renal Failure Prior organ transplantation 3 18.7% 2 12.5% Congestive Heart Failure 3 18.7% Re-exploration Neoplasia 3 18.7% 2 12.5% Prior PE 2 12.5% Bleeding Bacterial endocarditis 1 6.2% Hypercoagulable state 1 6.2% 2 12.5% Wound infection 1 6.2% LVEF 53.43 ± 7.68% ( 40-70 ) Cardiac arrest EF> 50% 6 37.5% 1 6.2% EF = 31-50% 10 62.5% LVEF (Left Ventricular Ejection Fraction) CPB (Cardiopulmonary Bypass); ICU (Intensive Care Unit)

Our Findings non-salvage salvage Early Mortality alive dead P=0.011 0 2 4 6 8 No. of patients Figure 2. Early mortality according to surgical modality (salvage vs. non-salvage). P < 0.05. Percent survival 100 75 50 25 salvage non-salvage p<0.05 0 0 10 20 30 40 days Figure 1. Kaplan Meier curves after surgical pulmonary embolectomy. In-Hospital survivals (salvage vs. non-salvage operations). P < 0.05. Mortality = 11% In patients with RVD undergoing early surgical embolectomy

Our Findings Table 4 Stratification of Risk of Death and recommended therapeutic option Risk of In-hospital Death Risk factor Recommended Treatment Cardiogenic Shock RV Dysfunction (based on echocardiogram) High Present Present Surgical Embolectomy Intermediate Absent Present * Consider Surgical Embolectomy Absent Absent Thrombolysis or conservative approach Low Absent Absent LMWH or Foundaparinux; consider outpatient treatment Adapted with modifications from Konstantinides et al.(2) and the 2008 Guidelines of the European Society of Cardiology * Recommendation for early surgical pulmonary embolectomy in hemodynamically stable patients with RV dysfunction